Evotec and Pfizer Collaborate on Groundbreaking Research for Metabolic and Infectious Diseases

Evotec SE, a leading life science company, has announced a multi-year master research collaboration and option and license agreement with Pfizer. The collaboration will initially focus on early discovery research for metabolic and infectious diseases. This partnership brings together the expertise and resources of both companies to explore potential new therapeutic approaches.

The research will be conducted at Evotec’s state-of-the-art research site, Campus Curie in Toulouse, France. The facility is equipped with advanced capabilities in high throughput screening, in vitro and in vivo biology, proteomics, and metabolomics. Evotec’s strong presence in France, with over 1,000 employees, contributes to the thriving biopharmaceutical ecosystem in the country.

Under the agreement, Pfizer will provide research support funding to Evotec. In addition, Evotec will be eligible for potential milestones and royalties based on the success of the programs. This collaboration highlights the commitment of both companies to addressing diseases with severe unmet medical needs and exploring highly innovative therapeutic approaches.

Dr. Matthias Evers, Chief Business Officer at Evotec, expressed his honor to collaborate with Pfizer in researching potential first-in-class therapeutic approaches. He also emphasized Evotec’s contribution to the French biopharmaceutical ecosystem and the company’s dedication to building a strong pipeline of medicines that matter.

Dr. Luca Mollo, Vice President and Medical Lead France at Pfizer, expressed his excitement about the collaboration with Evotec. He highlighted the importance of conducting discovery research to unlock new approaches for treating metabolic and infectious diseases that affect millions of patients worldwide. Dr. Mollo also acknowledged the strong biopharmaceutical ecosystem in France and the shared commitment of both companies to advancing scientific discovery for diseases with unmet needs.

Evotec is a life science company with a unique business model that focuses on discovering and developing highly effective therapeutics. The company’s multimodality platform combines innovative technologies, data, and science to create first-in-class and best-in-class pharmaceutical products. Evotec collaborates with top pharmaceutical companies, biotechnology companies, academic institutions, and other healthcare stakeholders to provide high-value pipeline co-creating partnerships and solutions.

With strategic activities in neurology, oncology, metabolic diseases, and infectious diseases, Evotec aims to create a world-leading co-owned pipeline for innovative therapeutics. The company has established a portfolio of over 200 proprietary and co-owned R&D projects, spanning from early discovery to clinical development.

Evotec operates globally with more than 5,000 highly qualified employees. The company’s sites in Europe and the USA synergistically combine technologies and services, operating as complementary clusters of excellence.

For additional information about Evotec, please visit their website at www.evotec.com. You can also follow them on Twitter @Evotec and LinkedIn.

More Posts

Bank First Corporation (NASDAQ: BFC) has announced its financial results for the second quarter of …

Universal Technical Institute, the transportation, skilled trades, and energy education division of Universal Technical Institute, …

EQT Corporation, a leading independent natural gas production company, has declared a quarterly cash dividend …